{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T14:27:04Z","timestamp":1782743224268,"version":"3.54.5"},"reference-count":51,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,6]],"date-time":"2024-05-06T00:00:00Z","timestamp":1714953600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jgisurgery.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Gastrointestinal Surgery"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.gassur.2024.05.001","type":"journal-article","created":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T15:42:53Z","timestamp":1715096573000},"page":"1104-1112","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Postoperative lenvatinib +\u00a0PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with microvascular invasion (Barcelona Clinic Liver Cancer stage 0 or A): a propensity score matching analysis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-1175-4034","authenticated-orcid":false,"given":"Awang","family":"Danzeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ling","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-hua","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng-wei","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-long","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingcuo","family":"Ciren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Run-hu","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue-wei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin-hao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.gassur.2024.05.001_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.gassur.2024.05.001_bib2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"10.1016\/j.gassur.2024.05.001_bib3","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1002\/hep.510300629","article-title":"Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation","volume":"30","author":"Llovet","year":"1999","journal-title":"Hepatology"},{"issue":"7","key":"10.1016\/j.gassur.2024.05.001_bib4","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1053\/j.gastro.2008.02.091","article-title":"Neither multiple tumors nor portal hypertension are surgical contraindications for hepatocellular carcinoma","volume":"134","author":"Ishizawa","year":"2008","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.gassur.2024.05.001_bib5","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/bjs.8915","article-title":"Systematic review of outcomes of liver resection for early hepatocellular carcinoma within the Milan criteria","volume":"99","author":"Lim","year":"2012","journal-title":"Br J Surg"},{"issue":"5","key":"10.1016\/j.gassur.2024.05.001_bib6","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.32411","article-title":"Dynamic risk profiling of HCC recurrence after curative intent liver resection","volume":"76","author":"Ivanics","year":"2022","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.gassur.2024.05.001_bib7","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","article-title":"Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy","volume":"38","author":"Imamura","year":"2003","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.gassur.2024.05.001_bib8","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1245\/s10434-008-9846-9","article-title":"Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors","volume":"15","author":"Sumie","year":"2008","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.gassur.2024.05.001_bib9","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jhep.2017.06.026","article-title":"Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: analysis of two phase III studies","volume":"67","author":"Bruix","year":"2017","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.gassur.2024.05.001_bib10","first-page":"61","article-title":"Adjuvant transcatheter arterial chemoembolization after curative resection for hepatocellular carcinoma patients with solitary tumor and microvascular invasion: a randomized clinical trial of efficacy and safety","volume":"38","author":"Wei","year":"2018","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.gassur.2024.05.001_bib11","article-title":"Efficacy of postoperative adjuvant transcatheter arterial chemoembolization in hepatocellular carcinoma patients with microscopic portal vein invasion","volume":"12","author":"Qiu","year":"2022","journal-title":"Front Oncol"},{"issue":"10","key":"10.1016\/j.gassur.2024.05.001_bib12","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1200\/JCO.22.01142","article-title":"Postoperative adjuvant hepatic arterial infusion chemotherapy with FOLFOX in hepatocellular carcinoma with microvascular invasion: a multicenter, Phase III, randomized study","volume":"41","author":"Li","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.gassur.2024.05.001_bib13","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejca.2022.02.012","article-title":"Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: a randomised controlled trial","volume":"166","author":"Shi","year":"2022","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.gassur.2024.05.001_bib14","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1159\/000514313","article-title":"Downstaging and resection of initially unresectable hepatocellular carcinoma with tyrosine kinase inhibitor and anti-PD-1 antibody combinations","volume":"10","author":"Zhu","year":"2021","journal-title":"Liver Cancer"},{"issue":"15","key":"10.1016\/j.gassur.2024.05.001_bib15","article-title":"PD-1 inhibitor combined with lenvatinib for unresectable liver cancer as the conversion therapy: an open-label, non-randomized, phase IV study","volume":"39","author":"Zhang","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10415","key":"10.1016\/j.gassur.2024.05.001_bib16","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/S0140-6736(23)01796-8","article-title":"Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Qin","year":"2023","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.gassur.2024.05.001_bib17","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1007\/s12072-022-10478-6","article-title":"Adjuvant anti-PD-1 antibody for hepatocellular carcinoma with high recurrence risks after hepatectomy","volume":"17","author":"Chen","year":"2023","journal-title":"Hepatol Int"},{"issue":"10","key":"10.1016\/j.gassur.2024.05.001_bib18","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s00535-023-02018-2","article-title":"Adjuvant immune checkpoint inhibitors associated with higher recurrence-free survival in postoperative hepatocellular carcinoma (PREVENT): a prospective, multicentric cohort study","volume":"58","author":"Li","year":"2023","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.gassur.2024.05.001_bib19","article-title":"Postoperative adjuvant tyrosine kinase inhibitors combined with anti-PD-1 antibodies improves surgical outcomes for hepatocellular carcinoma with high-risk recurrent factors","volume":"14","author":"Li","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.gassur.2024.05.001_bib20","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1007\/s11427-021-2079-7","article-title":"Expert consensus on organizing the multidisciplinary team (MDT) diagnosis and treatment of hepato-pancreato-biliary diseases in China","volume":"65","author":"Zhang","year":"2022","journal-title":"Sci China (Life Sci)"},{"issue":"1","key":"10.1016\/j.gassur.2024.05.001_bib21","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1245\/s10434-012-2513-1","article-title":"A systematic review of microvascular invasion in hepatocellular carcinoma: diagnostic and prognostic variability","volume":"20","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2013","journal-title":"Ann Surg Oncol"},{"issue":"3","key":"10.1016\/j.gassur.2024.05.001_bib22","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1053\/j.gastro.2009.06.003","article-title":"A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma","volume":"137","author":"Roayaie","year":"2009","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.gassur.2024.05.001_bib23","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1245\/s10434-013-3376-9","article-title":"The significance of classifying microvascular invasion in patients with hepatocellular carcinoma","volume":"21","author":"Sumie","year":"2014","journal-title":"Ann Surg Oncol"},{"issue":"42","key":"10.1016\/j.gassur.2024.05.001_bib24","doi-asserted-by":"crossref","first-page":"9279","DOI":"10.3748\/wjg.v22.i42.9279","article-title":"Practice guidelines for the pathological diagnosis of primary liver cancer: 2015 update","volume":"22","author":"Cong","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gassur.2024.05.001_bib25","first-page":"7","article-title":"Surgical anatomy of the liver and liver resection. Brisbane 2000 Terminology","volume":"104","author":"Popescu","year":"2009","journal-title":"Chirurgia (Bucur)"},{"issue":"4","key":"10.1016\/j.gassur.2024.05.001_bib26","first-page":"346","article-title":"Ultrasonically guided subsegmentectomy","volume":"161","author":"Makuuchi","year":"1985","journal-title":"Surg Gynecol Obstet"},{"issue":"3","key":"10.1016\/j.gassur.2024.05.001_bib27","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jhep.2015.10.015","article-title":"Complete removal of the tumor-bearing portal territory decreases local tumor recurrence and improves disease-specific survival of patients with hepatocellular carcinoma","volume":"64","author":"Shindoh","year":"2016","journal-title":"J Hepatol"},{"issue":"29","key":"10.1016\/j.gassur.2024.05.001_bib28","doi-asserted-by":"crossref","first-page":"3603","DOI":"10.3748\/wjg.v16.i29.3603","article-title":"Non-viral causes of hepatocellular carcinoma","volume":"16","author":"Blonski","year":"2010","journal-title":"World J Gastroenterol"},{"issue":"5","key":"10.1016\/j.gassur.2024.05.001_bib29","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.surg.2010.12.002","article-title":"Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver Surgery","volume":"149","author":"Koch","year":"2011","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.gassur.2024.05.001_bib30","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1097\/01.sla.0000189131.90876.9e","article-title":"The \u201c50-50 criteria\u201d on postoperative day 5: an accurate predictor of liver failure and death after hepatectomy","volume":"242","author":"Balzan","year":"2005","journal-title":"Ann Surg"},{"issue":"2","key":"10.1016\/j.gassur.2024.05.001_bib31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.gassur.2024.05.001_bib32","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1097\/00000478-200201000-00003","article-title":"Prognostic histologic indicators of curatively resected hepatocellular carcinomas: a multi-institutional analysis of 425 patients with definition of a histologic prognostic index","volume":"26","author":"Lauwers","year":"2002","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.gassur.2024.05.001_bib33","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.gassur.2024.05.001_bib34","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/SLA.0b013e318295c160","article-title":"Hypoxia after liver surgery imposes an aggressive cancer stem cell phenotype on residual tumor cells","volume":"259","author":"Govaert","year":"2014","journal-title":"Ann Surg"},{"issue":"1","key":"10.1016\/j.gassur.2024.05.001_bib35","doi-asserted-by":"crossref","first-page":"8935","DOI":"10.1038\/s41598-018-27319-y","article-title":"Ischemia-reperfusion injury and the risk of hepatocellular carcinoma recurrence after deceased donor liver transplantation","volume":"8","author":"Gr\u0105t","year":"2018","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.gassur.2024.05.001_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s12943-019-1058-3","article-title":"Surgical stress and cancer progression: the twisted tango","volume":"18","author":"Chen","year":"2019","journal-title":"Mol Cancer"},{"issue":"20","key":"10.1016\/j.gassur.2024.05.001_bib37","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.gassur.2024.05.001_bib38","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/s41577-019-0218-4","article-title":"Tumour-intrinsic resistance to immune checkpoint blockade","volume":"20","author":"Kalbasi","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"6230","key":"10.1016\/j.gassur.2024.05.001_bib39","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.gassur.2024.05.001_bib40","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semcancer.2018.06.002","article-title":"The reciprocal function and regulation of tumor vessels and immune cells offers new therapeutic opportunities in cancer","volume":"52","author":"Missiaen","year":"2018","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.gassur.2024.05.001_bib41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000496277","article-title":"Combination cancer immunotherapy with molecular targeted agents\/anti-CTLA-4 antibody for hepatocellular carcinoma","volume":"8","author":"Kudo","year":"2019","journal-title":"Liver Cancer"},{"issue":"5","key":"10.1016\/j.gassur.2024.05.001_bib42","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"18","key":"10.1016\/j.gassur.2024.05.001_bib43","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.gassur.2024.05.001_bib44","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.gassur.2024.05.001_bib45","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.pharmthera.2017.02.005","article-title":"Tumor regulation of the tissue environment in the liver","volume":"173","author":"Eggert","year":"2017","journal-title":"Pharmcol Ther"},{"issue":"25","key":"10.1016\/j.gassur.2024.05.001_bib46","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.3748\/wjg.v25.i25.3151","article-title":"Hepatocellular carcinoma: mechanisms of progression and immunotherapy","volume":"25","author":"Jiang","year":"2019","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.gassur.2024.05.001_bib47","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.hpb.2019.12.013","article-title":"A systematic review and meta-analysis of adjuvant transarterial chemoembolization after curative resection for patients with hepatocellular carcinoma","volume":"22","author":"Chen","year":"2020","journal-title":"HPB (Oxf)"},{"issue":"6","key":"10.1016\/j.gassur.2024.05.001_bib48","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1177\/0284185119878357","article-title":"Postoperative adjuvant transarterial chemoembolization improves the prognosis of hepatocellular carcinoma patients with microvascular invasion: a systematic review and meta-analysis","volume":"61","author":"Li","year":"2020","journal-title":"Acta Radiol"},{"issue":"2","key":"10.1016\/j.gassur.2024.05.001_bib49","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.jhep.2019.10.021","article-title":"Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"72","author":"Sangro","year":"2020","journal-title":"J Hepatol"},{"issue":"7 Pt 2","key":"10.1016\/j.gassur.2024.05.001_bib50","first-page":"e189","article-title":"Clinical significance of alpha-fetoprotein: involvement in proliferation, angiogenesis, and apoptosis of hepatocellular carcinoma","volume":"23","author":"Mitsuhashi","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gassur.2024.05.001_bib51","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/j.jhep.2014.01.027","article-title":"Prediction of aggressiveness in early-stage hepatocellular carcinoma for selection of surgical resection","volume":"60","author":"Suh","year":"2014","journal-title":"J Hepatol"}],"container-title":["Journal of Gastrointestinal Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X24004426?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091255X24004426?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,2]],"date-time":"2024-07-02T13:13:31Z","timestamp":1719926011000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091255X24004426"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":51,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S1091255X24004426"],"URL":"https:\/\/doi.org\/10.1016\/j.gassur.2024.05.001","relation":{},"ISSN":["1091-255X"],"issn-type":[{"value":"1091-255X","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Postoperative lenvatinib +\u00a0PD-1 blockade reduces early tumor recurrence in hepatocellular carcinoma with microvascular invasion (Barcelona Clinic Liver Cancer stage 0 or A): a propensity score matching analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Gastrointestinal Surgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gassur.2024.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of Society for Surgery of the Alimentary Tract.","name":"copyright","label":"Copyright"}]}}